Perifosine in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Status:
Completed
Trial end date:
2013-04-01
Target enrollment:
Participant gender:
Summary
Perifosine inhibits the AKT pathway (a way cells communicate with each other). This pathway
is felt to be important in the development of several types of cancers including chronic
lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It is thought perifosine may
be able to block this pathway and lead to an improvement in the CLL or SLL. The purpose of
this trial is to see if perifosine is an effective treatment for relapsed or refractory CLL
or SLL. Another purpose of this study is to look at the effect perifosine has on cells.
Phase:
Phase 2
Details
Lead Sponsor:
Daphne Friedman
Collaborators:
Keryx / AOI Pharmaceuticals, Inc. Keryx Biopharmaceuticals